Evidence map›Paper›PMID 32493337›Full record

ArticleBMC public health2020

"Death is a better option than being treated like this": a prevalence survey and qualitative study of depression among multi-drug resistant tuberculosis in-patients.

R Huque, H Elsey, F Fieroze, J P Hicks, S Huque, P Bhawmik, I Walker, J Newell

Open access · goldAbstract read
In one paragraph

Article in BMC public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

R HuqueThe ARK Foundation, Suite C-3 & C-4, House 06, Road 109, Gulshan-2, Dhaka-1212, Dhaka, Bangladesh.
H ElseyDepartment of Health Sciences, University of York, Seebohm Rowntree Building, York, YO10 5DD, UK. helen.elsey@york.ac.uk.ORCID http://orcid.org/0000-0003-4724-0581
F FierozeThe ARK Foundation, Suite C-3 & C-4, House 06, Road 109, Gulshan-2, Dhaka-1212, Dhaka, Bangladesh.
J P HicksLeeds Institute of Health Sciences, University of Leeds, 10.31 Worsley, Leeds, LS2 9JT, UK.
S HuqueThe ARK Foundation, Suite C-3 & C-4, House 06, Road 109, Gulshan-2, Dhaka-1212, Dhaka, Bangladesh.
P BhawmikThe ARK Foundation, Suite C-3 & C-4, House 06, Road 109, Gulshan-2, Dhaka-1212, Dhaka, Bangladesh.
I WalkerLeeds Institute of Health Sciences, University of Leeds, 10.31 Worsley, Leeds, LS2 9JT, UK.
J NewellLeeds Institute of Health Sciences, University of Leeds, 10.31 Worsley, Leeds, LS2 9JT, UK.
ARK Foundation · BDUniversity of Leeds · GBUniversity of York · GB

Funding

DFID DFID RPC COMDIS HSD
6 · The paper itself

Abstract

backgroundUnderstanding of the relationship between multi-drug resistant tuberculosis and mental health is limited. With growing prevalence of multi-drug resistant tuberculosis, addressing mental ill-health has potential to improve treatment outcomes and well-being. In several low and middle-income contexts hospitalisation during treatment is common. Understanding of the impact on mental ill-health are required to inform interventions for patients with multi-drug resistant tuberculosis. Our aim was to identify the prevalence of comorbid depression among in-patients being treated for multi-drug resistant tuberculosis and to explore their experiences of comorbid disease and the care they received in a large specialist chest hospital in Dhaka, Bangladesh.

methodsWe conducted a quantitative cross-sectional survey among 150 multi-drug resistant tuberculosis in-patients (new cases = 34%, previously treated = 66%) in 2018. A psychiatrist assessed depression was assessed with the Structured Clinical Interview for Depression (SCID DSM-IV). We used multi-level modelling to identify associations with depression. Experience Bangladeshi researchers conducted qualitative interviews with 8 patients, 4 carers, 4 health professionals and reflective notes recorded. Qualitative data was analysed thematically.

resultsWe found 33.8% (95% CI 26.7%; 41.7%) of patients were depressed. While more women were depressed 39.3% (95% CI 27.6%; 52.4%) than men 30.4% (95% CI 22%; 40.5%) this was not significant. After controlling for key variables only having one or more co-morbidity (adjusted odds ratio [AOR] = 2.88 [95% CI 1.13; 7.33]) and being a new rather than previously treated case (AOR = 2.33 [95% CI 1.06; 5.14]) were associated (positively) with depression. Qualitative data highlighted the isolation and despair felt by patients who described a service predominantly focused on providing medicines. Individual, familial, societal and health-care factors influenced resilience, nuanced by gender, socio-economic status and home location.

conclusionsPatients with multi-drug resistant tuberculosis are at high risk of depression, particularly those with co- and multi-morbidities. Screening for depression and psycho-social support should be integrated within routine TB services and provided throughout treatment.

Indexed as

Attitude to DeathAdultAntitubercular AgentsBangladeshComorbidityCross-Sectional StudiesDepressionDeveloping CountriesFemaleHumansIncomeMaleMiddle AgedMultilevel AnalysisOdds RatioPrevalenceAntitubercular AgentsBangladeshCo-morbiditiesDepressionLow and middle income countries (LMIC)Mental healthMulti-drug resistant (MDR-TB)Tuberculosis (TB)

Identifiers

PMID32493337
PMCPMC7268321
OpenAlexW3030127794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.